<DOC>
	<DOC>NCT01519089</DOC>
	<brief_summary>The main objective of this study is to evaluate the long term safety of CP-690,550 in patients being treated for moderate to severe plaque psoriasis and/or psoriatic arthritis. This study will also to compare the efficacy of two oral doses of CP-690,550 (5 mg BID and 10 mg BID) after 16 weeks of treatment.</brief_summary>
	<brief_title>A Long Term Study To Evaluate The Safety, Tolerability And Efficacy Of CP-690,550 In Patients With Moderate To Severe Plaque Psoriasis And/Or Psoriatic Arthritis</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Arthritis, Psoriatic</mesh_term>
	<mesh_term>Tofacitinib</mesh_term>
	<criteria>Are 20 years or older and considered to be candidates for systemic or phototherapy. [Moderate to Severe Plaque Psoriasis] Diagnosed for at least 12 months. Have Psoriasis Area and Severity Index (PASI) score of 12 and plaque type psoriasis covering at least 10% of body surface area (BSA). [Psoriatic Arthritis] Diagnosed for at least 6 months. Meet the CASPAR (classification criteria for Psoriatic Arthritis) criteria at screening; Have active arthritis (≥3 tender/painful joints on motion and ≥3 swollen joints), and active plaque psoriasis with at least 2 cm in diameter. Nonplaque or drug induced forms of psoriasis Cannot discontinue current oral, injectable or topical therapy for psoriasis/psoriatic arthritis or cannot discontinue phototherapy (PUVA or UVB) any uncontrolled significant medical condition</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2015</verification_date>
	<keyword>chronic</keyword>
	<keyword>severe</keyword>
	<keyword>moderate</keyword>
	<keyword>treatment</keyword>
	<keyword>safety</keyword>
	<keyword>efficacy</keyword>
	<keyword>CP-690</keyword>
	<keyword>550</keyword>
	<keyword>Plaque psoriasis</keyword>
	<keyword>Psoriasis Vulgaris</keyword>
	<keyword>Psoriatic Arthritis</keyword>
	<keyword>tofacitinib</keyword>
	<keyword>Xeljanz</keyword>
</DOC>